We focus on medical technology investments in companies targeting large unmet clinical needs. We will invest in high growth areas and in companies solving major clinical problems while balancing that with focused capital efficient development plans. We take a balanced approach in building our portfolio with some early stage investments, where the prior seed stage investment has proved the feasibility of a concept, and some later stage investments, where clinical data has shown efficacy and the company is in a “scale-up for commercialization” mode.
We will also invest in opportunities generated by NuXcel, our own medical device accelerator with a presence in Silicon Valley, Minneapolis, and Ireland.
S.H.I.P. leverages its relationships and unique set of LPs to improve the speed and quality of development of new products and their commercialization globally.